Gene-Disorder Association · Article
Gene
FGFR3 Fibroblast Growth Factor Receptor 3
×
First reported
2001
Supporting publications
63
Manually curated Approved treatment annotated
Association Review
In brief The association between FGFR3 (Fibroblast Growth Factor Receptor 3) and Bladder Cancer is well established and manually curated, with its 4 contributing sources — 3 of them expert-curated — recording a known molecular basis, pathogenic variants, and causative variation.
Sources
4
Clinical variants
38
Symptoms
4
Compounds
4
Trials
238 of 7,351 via FGFR3 compounds
Publications
63
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 4 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 3 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Bladder Cancer
The disorder 17 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Phenotype
Clinical features 2 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access 06
ClinVar and variant evidence
Genetic basis 38 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access 07
Population genetics
GWAS signals 1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access 08
Mechanism overlap
Shared mechanisms 1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 09
Interventions
Therapeutics 4 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 10
Human studies
Clinical trials 7,351 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 63 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 12
Provenance
References & sources 22 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
